DOCSLIB.ORG

Effects of Sustained Treatment with Lixisenatide On

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Sustained Treatment with Lixisenatide On EMERGING THERAPIES: DRUGS AND REGIMENS Diabetes Care 1 Christopher K. Rayner,1,2 Linda E. Watson,1 Effects of Sustained Treatment Liza K. Phillips,1,3 Kylie Lange,1 Michelle J. Bound,1 Jacqueline Grivell,1 With Lixisenatide on Gastric Tongzhi Wu,1,3 Karen L. Jones,1,3 Michael Horowitz,1,3 Ele Ferrannini,4 Emptying and Postprandial Domenico Trico,` 5 Silvia Frascerra,6 Glucose Metabolism in Type 2 Andrea Mari,7 and Andrea Natali6 Diabetes: A Randomized Controlled Trial https://doi.org/10.2337/dc20-0190 OBJECTIVE Tachyphylaxis for slowing of gastric emptying is seen with continuous exposure to glucagon-like peptide 1 (GLP-1). We therefore aimed to establish whether prolonged use of a “short-acting” GLP-1 receptor agonist, lixisenatide, achieves sustained slowing of gastric emptying and reduction in postprandial glycemia. RESEARCH DESIGN AND METHODS 1Centre of Research Excellence for Translating A total of 30 patients with metformin-treated type 2 diabetes underwent assessment Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia of gastric emptying (scintigraphy) and glucose metabolism (dual tracer technique) 2Department of Gastroenterology and Hepatol- aftera75-gglucosedrink,beforeandafter8weeks’treatmentwithlixisenatide(20mg ogy, Royal Adelaide Hospital, Adelaide, Australia subcutaneously daily) or placebo, in a double-blind randomized parallel design. 3Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia RESULTS 4CNR Institute of Clinical Physiology, Pisa, Italy 5Department of Surgical, Medical and Molecular Gastric retention of the glucose drink was markedly increased after lixisenatide Pathology and Critical Care Medicine, University versus placebo (ratio of adjusted geometric means for area under curve [AUC] over of Pisa, Pisa, Italy 240min of 2.19[95%CI 1.82, 2.64;P< 0.001]), associatedwith substantial reductions 6Department of Clinical and Experimental Med- in the rate of systemic appearance of oral glucose (P < 0.001) and incremental AUC icine, University of Pisa, Pisa, Italy 7CNR Institute of Neuroscience, Padua, Italy for blood glucose (P < 0.001). Lixisenatide suppressed both glucagon (P 5 0.003) and P 5 Corresponding author: Christopher K. Rayner, insulin ( 0.032), but not endogenous glucose production, over 120 min after oral [email protected] glucose intake. Postprandial glucose lowering over 240 min was strongly related to Received 27 January 2020 and accepted 28 April the magnitude of slowing of gastric emptying by lixisenatide (r 520.74, P 5 0.002) 2020 and to the baseline rate of emptying (r 5 0.52, P 5 0.048) but unrelated to b-cell Clinical trial reg. no. ACTRN12616001059459, function (assessed by b-cell glucose sensitivity). www.anzctr.org.au This article contains supplementary material online CONCLUSIONS at https://doi.org/10.2337/figshare.12245516. Eight weeks’ treatment with lixisenatide is associated with sustained slowing of © 2020 by the American Diabetes Association. gastric emptying and marked reductions in postprandial glycemia and appearance Readers may use this article as long as the work is properly cited, the use is educational and not for of ingested glucose. Short-acting GLP-1 receptor agonists therefore potentially fi fi pro t, and the work is not altered. More infor- represent an effective long-term therapy for speci cally targeting postprandial mation is available at https://www.diabetesjournals glucose excursions. .org/content/license. Diabetes Care Publish Ahead of Print, published online May 29, 2020 2 Gastric Emptying With Sustained Lixisenatide Diabetes Care Early intervention to achieve good gly- The evolution of type 2 diabetes is Study Design cemic control in type 2 diabetes can characterized by progressive b-cell After enrolment, participants were ran- reduce the risk of micro- and potentially failure, which entails a loss of insulin domized to treatment with lixisenatide macrovascular complications but entails secretory capacity and, eventually, a re- or placebo in a double-blind parallel risks, particularly for insulin therapy, of duction in b-cell mass (16). A therapy that design. Patients attended our Clinical weight gain and hypoglycemia (1). Re- targets postprandial glycemia, without Research Facility for a baseline study cent guidelines recommend an individ- the requirement to stimulate insulin se- where a glucose drink was administered ualizedapproachtotheselectionof cretion, is an attractive therapeutic op- (day 0) before commencing treatment second-line pharmacological treatment tion, and there is recent evidence that with daily subcutaneous injections from after metformin (2). In the majority of lixisenatide maintains its efficacy for day 1 to day 56. They attended the type 2 patients in the community, who lowering HbA1c across the spectrum of laboratory for a second study on the have relatively modest elevation of gly- b-cell function in patients with type 2 last day of treatment (day 56), when fi cated hemoglobin (HbA1c) (3), postpran- diabetes (17). they received their nal dose of lixise- dial rather than fasting blood glucose We aimed to evaluate the effects of natide or placebo 30 min before the plays an important role in overall glyce- sustained use of lixisenatide on gastric glucose test drink. mic control (4), which is not surprising emptying, using the most accurate tech- On each of the two study days (days given that humans are predominantly in nique of scintigraphy, and on postpran- 0 and 56), patients attended our facility the postprandial state. It is now apparent dial glucose metabolism, using a dual in the morning (0800 h) after an over- that postprandial glycemia must be spe- glucose tracer technique (18), in patients night fast, having consumed a standard- cifically targeted in patients with diabe- with relatively well-controlled type 2 di- ized beef lasagne meal the previous tes, particularly in those who have only abetes treated with metformin alone. We evening. An intravenous (IV) cannula moderately elevated HbA1c with minimal hypothesized that, as a short-acting GLP-1 wasinsertedineachforearm:onefor fasting hyperglycemia (5). receptor agonist, lixisenatide would have blood sampling and the other for IV The gut-derived incretin hormone, glu- persistingeffectstoslowgastricemptying infusion of glucose tracer (bolus of 21 2 cagon-like peptide 1 (GLP-1), has several with sustained use and that this would 28 mmol z kg 6,6-[ H2]glucose, fol- actions that lower glycemia, including be a dominant mechanism by which it lowed by continuous infusion at a 2 2 slowing of gastric emptying, glucose- achieves postprandial blood glucose rate of 0.28 mmol z min 1 z kg 1 dependent stimulation of insulin, and sup- control. from t 52180 until t 5 240 min). At pression of glucagon (6–8), all of which t 525 min, a 300-mL drink was given potentially impact on the systemic ap- RESEARCH DESIGN AND METHODS while the subject sat against a g camera, pearance of orally ingested carbohydrate Subjects consisting of 75-g glucose, labeled with and the rate of endogenous glucose We recruited, by advertisement, patients 20 MBq 99mTc-calcium phytate, and also production. The rate at which nutrients with a history of type 2 diabetes of $2 containing 1.5 g [U-13C]glucose. The drink empty from the stomach is a particularly years’ duration, treated with metformin was consumed within 5 min, and scinti- important determinant of postprandial for $3 months. Responders who met graphic imaging continued for 240 min, glycemia in health and type 2 diabetes (9), eligibility criteria attended our facility with correction of data for subject move- and pharmacological agents that slow gas- for a screening visit, when fasting blood ment, radionuclide decay, and g-ray tric emptying result in a lowering of the samples were collected for blood picture, attenuation (21). Gastric retention (ex- postprandial blood glucose excursion (10). iron studies, biochemistry, and HbA1c; pressed as % of the maximum content A number of GLP-1 receptor agonists autonomic function was evaluated by of the total stomach) was calculated at have been developed for the treatment standardized cardiovascular tests (19); 15-min intervals for the first 120 min of type 2 diabetes; these differ in being and gastrointestinal symptoms were andthenhourlyuntilt 5 240 min. “short acting” (e.g., lixisenatide or ex- evaluated by questionnaire (20). Those Venous blood was sampled at frequent 21 enatide BD) or “long acting” (e.g., liraglu- with HbA1c ,6.5% (48 mmol z mol ) intervals for measurement of blood tide or exenatide QW). There is recent or .9.0% (75 mmol z mol21), estimated glucose and plasma concentrations of evidence that continuous exposure to glomerular filtration rate ,30 mL z min21, glucosetracers,insulin,C-peptide,and GLP-1is associated withtachyphylaxis for definite autonomic neuropathy, elevated glucagon. A fasting sample was also its effects on gastric emptying (11,12). liver enzymes, hospital admission for car- collected on day 56 to measure HbA1c. Consistent with this concept, postpran- diovascular disease within the previous dial glycemia appears to be better con- 6 months, previous exposure to GLP-1 Intervention trolled after several weeks’ treatment receptor agonists, or prominent gastro- On days 1–56 inclusive, each subject self- with short-acting versus long-acting GLP- intestinal symptoms or using medications administered lixisenatideor matchingpla- 1 receptor agonists, although typically in known to affect gastrointestinal motility cebo (saline) subcutaneously
Load more

Recommended publications
  • GLP-1 Receptor Agonists
    Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. GLP-1 Receptor Agonists Evidence Summary GLP-1 agonists are beneficial for patients with type 2 diabetes and obesity. Some evidence suggests benefits for Alzheimer’s disease. It is unclear whether it is beneficial for individuals without underlying metabolic disease. Semaglutide seems to be most effective for metabolic dysfunction, though liraglutide has more preclinical data for Alzheimer’s disease. Neuroprotective Benefit: Evidence from many preclinical studies and a pilot biomarker study suggest some neuroprotective benefits with GLP-1 agonists. However, whether they may be beneficial for everyone or only a subset of individuals (e.g. diabetics) is unclear. Aging and related health concerns: GLP-1 agonists are beneficial for treating diabetes and cardiovascular complications relating to diabetes. It is not clear whether they have beneficial effects in otherwise healthy individuals. Safety: GLP-1 agonists are generally safe for most people with minor side effects. However, long-term side effects are not known. 1 Availability: Available Dose: Varies - see Chemical formula: C172H265N43O51 (Liraglutide) as a prescription chart at the end of MW: 3751.262 g/mol medicine.
    [Show full text]
  • Combining a Glucagon-Like Peptide-1 Receptor Agonist with Basal Insulin: the Why and How
    Combining a Glucagon-like Peptide-1 Receptor Agonist with Basal Insulin: The Why and How Case Study Mary is a 61 year-old female diagnosed with type 2 diabetes mellitus (T2DM) 8 years ago. She was initially managed with the combination of lifestyle modification and metformin. Since that time she was treated with a sulfonylurea, but it was discontinued due to symptomatic hypoglycemia. She was also treated with pioglitazone, but significant fluid retention led to it discontinuation. A year-and-a- half ago, basal insulin was added to her lifestyle and metformin management. She now administers 52 units (0.62 units/kg) once daily at bedtime. Since starting basal insulin, she has experienced 3 episodes of mild hypoglycemia. Since her diagnosis, Mary’s HbA1c has never been <7.0%; her current HbA1c is 7.9%. Over the past month, her fasting plasma glucose (FPG) has ranged from 103 mg/dL to 136 mg/dL and her postprandial glucose (PPG) from 164 mg/dL to 213 mg/dL. She has gained 2.6 kg since starting basal insulin and her body mass index is now 31 kg/m2. Her blood pressure is 134/82 mmHg. She experiences occasional tingling in her feet. Eye examination reveals grade 1 retinopathy. Current medications are: metformin 1000mg twice daily, basal insulin 52 units once daily at bedtime, and hydrochlorothiazide 25 mg once daily. Her family physician notes that Mary’s FPG is reasonably well-controlled, yet her HbA1c and PPG remain elevated. He is also concerned about her episodes of hypoglycemia and weight gain and the evidence indicating microvascular damage.
    [Show full text]
  • A Network Meta-Analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
    Diabetes Ther DOI 10.1007/s13300-016-0155-1 REVIEW A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus Sheena Kayaniyil . Greta Lozano-Ortega . Heather A. Bennett . Kristina Johnsson . Alka Shaunik . Susan Grandy . Bernt Kartman To view enhanced content go to www.diabetestherapy-open.com Received: December 17, 2015 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT treatment of adults with T2DM inadequately controlled on metformin monotherapy. Introduction: Exenatide is a glucagon-like Methods: A systematic literature review was peptide-1 receptor agonist (GLP-1 RA), conducted to identify randomized controlled approved for treatment of type 2 diabetes trials (RCTs) that investigated GLP-1 RAs mellitus (T2DM). There is limited direct (albiglutide, dulaglutide, exenatide, liraglutide, evidence comparing the efficacy and and lixisenatide) at approved doses in the tolerability of exenatide 2 mg once weekly United States/Europe, added on to metformin (QW) to other GLP-1 RAs. A network only and of 24 ± 6 weeks treatment duration. meta-analysis (NMA) was conducted to A Bayesian NMA was conducted. estimate the relative efficacy and tolerability of Results: Fourteen RCTs were included in the exenatide QW versus other GLP-1 RAs for the NMA. Exenatide QW obtained a statistically significant reduction in glycated hemoglobin (HbA1c) relative to lixisenatide 20 lg once daily. No other comparisons of exenatide QW Electronic supplementary material The online version of this article (doi:10.1007/s13300-016-0155-1) to other GLP-1 RAs were statistically significant contains supplementary material, which is available to for change in HbA1c.
    [Show full text]
  • GLP-1 Receptor Agonists Reference Number: CP.HNMC.16 Effective Date: 11.16.16 Last Review Date: 11.17 Revision Log Line of Business: Medicaid – Medi-Cal
    Clinical Policy: GLP-1 Receptor Agonists Reference Number: CP.HNMC.16 Effective Date: 11.16.16 Last Review Date: 11.17 Revision Log Line of Business: Medicaid – Medi-Cal See Important Reminder at the end of this policy for important regulatory and legal information. Description The following are GLP-1 Receptor Agonists requiring prior authorization: lixisenatide (Adlyxin™), Exenatide Extended-Release (Bydureon®), Exenatide (Byetta®), Pramlintide Acetate (Symlin®), Albiglutide (Tanzeum®), Dulaglutide (Trulicity®), Liraglutide (Victoza®), Liraglutide and insulin degludec (Xultophy®),Insulin glargine and lixisenatide (Soliqua®). FDA approved indication Adlyxin, Bydureon, Byetta, Tanzeum, Trulicity, Victoza are indicated: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Adlyxin limitation of use: Has not been studied in patients with chronic pancreatitis or a history of unexplained pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. Not for treatment of type 1 diabetes or diabetic ketoacidosis. Has not been studied in combination with short acting insulin. Has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis. Bydureon limitation of use: Not recommended as first-line therapy for patients inadequately controlled on diet and exercise. Should not be used to treat type 1 diabetes or diabetic ketoacidosis. Use with insulin has not been studied and is not recommended. Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. Byetta limitation of use: Not a substitute for insulin. Byetta should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis.
    [Show full text]
  • Changing Lives with Next Generation Peptide Therapeutics
    Changing lives with next generation peptide therapeutics Zealand Pharma Corporate Presentation May 2019 Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the information contained in this presentation or any other information transmitted or made available to the viewer or recipient hereof, whether communicated in written or oral form. This presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire Zealand securities, in any jurisdiction, or an inducement to enter into investment activity, nor shall there be any sale of Zealand securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation contains forward-looking statements that reflect management's current views with respect to Zealand's product candidates' development, clinical and regulatory timelines and anticipated results, market opportunity, potential financial performance and other statements of future events or conditions. Although Zealand believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct.
    [Show full text]
  • Discovery of Lixisenatide Analogues As Long-Acting Hypoglycemic Agents Using Novel Peptide Half-Life Extension Technology Based
    RSC Advances View Article Online PAPER View Journal | View Issue Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life Cite this: RSC Adv., 2020, 10,12089 extension technology based on mycophenolic acid† Chunli Tang,‡ac Qing Li,‡d Xiaoyan Deng,d Weiwei Wu,a Liufeng Liao,a Kai Liang,a Rongrui Huo,c Chenglin Li,e Jing Han, *f Weizhong Tang*b and Neng Jiang*a Noncovalent binding of peptides to human serum albumin protects against renal clearance and enzymatic degradation. Herein, we investigated the effect of mycophenolic acid (MPA) albumin binders for improving the stability of peptides. For proof-of-principle, the short acting glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide was selected and functionalized with different MPA albumin binders. In vitro, all lixisenatide analogues showed well preserved GLP-1 receptor activation potency. High performance affinity chromatography (HPAC) and ultrafiltration analyses indicated that DiMPA was able to confer high Creative Commons Attribution-NonCommercial 3.0 Unported Licence. albumin affinity to lixisenatide and revealed that affinity is increased for DiMPA modified lixisenatide analogues containing OEG spacers. In db/db mice, the selected peptide 2c showed comparable efficacies to lixisenatide with respect to glucose-lowering and insulinotropic activities. Furthermore, the duration of action of glucose homeostasis of 2c was comparable to semaglutide in db/db mice. Importantly, DiMPA albumin binder did not bring significant toxicity of lixisenatide, as reflected by the comparable toxicity indexes in 2c and semaglutide groups after 2 weeks dosing in normal Kunming mice. Short-term study (21 days) conducted on db/db mice showed the better therapeutic efficacies of 2c than semaglutide on pancreas islets protection.
    [Show full text]
  • Prandial Options to Advance Basal Insulin Glargine Therapy
    1318 Diabetes Care Volume 39, August 2016 Julio Rosenstock,1 Bruno Guerci,2 Prandial Options to Advance Basal Markolf Hanefeld,3 Sandro Gentile,4 Ronnie Aronson,5 Francisco J. Tinahones,6 Insulin Glargine Therapy: Testing Christine Roy-Duval,7 Elisabeth Souhami,7 Marek Wardecki,8 Jenny Ye,9 Lixisenatide Plus Basal Insulin Riccardo Perfetti,9 and Simon Heller,10 on behalf of the GetGoal Duo-2 Trial Versus Insulin Glulisine Either as Investigators Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial Diabetes Care 2016;39:1318–1328 | DOI: 10.2337/dc16-0014 CLIN CARE/EDUCATION/NUTRITION/PSYCHOSOCIAL OBJECTIVE To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1–3 oral antidi- 1Dallas Diabetes and Endocrine Center at Medi- abetic agents (OADs). cal City, Dallas, TX 2University of Lorraine and the Department of RESEARCH DESIGN AND METHODS Diabetology, Metabolic Diseases and Nutrition, Brabois Adult Hospital, Vandœuvre-les-Nancy,` Patients were randomized to lixisenatide once daily or insulin glulisine given once France 3 or thrice daily, added to glargine, with or without metformin, if HbA1c remained GWT-TUD, Study Centre Prof. Hanefeld, Dres- ‡7to£9% (‡53 to £75 mmol/mol) after 12 weeks of glargine optimization with den Technical University, Dresden, Germany 4Department of Clinical and Experimental Med- OADs other than metformin stopped at the start
    [Show full text]
  • Soliqua 100/33 Dosing and Gradual Titration Guide
    SOLIQUA 100/33 DOSING AND GRADUAL TITRATION GUIDE SOLIQUA 100/33 is a combination of a long-acting human insulin analog with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: n Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. n Not recommended for use in combination with any other product containing a GLP-1 receptor agonist. n Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis. n Not recommended for use in patients with gastroparesis. n Has not been studied in combination with prandial insulin. Important Safety Information Contraindications Not actual patients n During episodes of hypoglycemia. n In patients with known hypersensitivity to the active substance(s) or to any of the product components. Please see full Important Safety Information on page 4. Click here for full Prescribing Information. THE POWER TO GET TO GOAL 1 SOLIQUA 100/33 allows for gradual titration of the GLP-1 RA along with the basal insulin Titration of stand-alone GLP-1 RA (lixisenatide) Gradual titration of SOLIQUA 100/33 Maintenance 60 20 19 18 50 17 16 15 14 40 Initiation 13 12 11 GLP-1 RA Dose 30 10 GLP-1 RA (mcg) Basal insulin (Units) 9 8 20 7 6 15 5 Time Time Important Safety Information Warnings and Precautions n Anaphylaxis and Serious Hypersensitivity Reactions: In clinical trials of lixisenatide, there have been cases of anaphylaxis and other serious hypersensitivity reactions including angioedema.
    [Show full text]
  • Insulin and Combination Agents
    Therapeutic Class Overview Insulin and Combination Agents INTRODUCTION Diabetes mellitus is defined as a group of metabolic disorders characterized by hyperglycemia that result from defects in the secretion and action of insulin (American Diabetes Association [ADA] Diabetes Basics 2018). The classification of diabetes includes four clinical classes: 1) Type 1 diabetes (T1DM) which results from beta-cell (β- cell) destruction, usually leading to absolute insulin deficiency; 2) Type 2 diabetes (T2DM) which results from a progressive insulin secretory defect on the background of insulin resistance; 3) Other specific types of diabetes due to other causes, e.g., genetic defects in β-cell function, genetic defects in insulin action, diseases of the exocrine pancreas (such as cystic fibrosis), and drug- or chemical-induced (such as in the treatment of HIV/AIDS or after organ transplantation; and 4) Gestational diabetes mellitus (diabetes diagnosed during pregnancy that is not clearly overt diabetes) (ADA 2018). In 2015, an estimated 30.3 million people, or 9.4%, of the United States (US) population had diabetes mellitus, with 7.2 million estimated to be undiagnosed (Centers for Disease Control and Prevention [CDC] 2017). The insulin products are approved for use in the management of both T1DM and T2DM. Other pharmacologic options for T2DM include sulfonylureas, biguanides, thiazolidinediones, meglitinides, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, amylinomimetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and combination products. Insulin is used as replacement therapy in patients with diabetes, replacing deficient endogenous insulin and temporarily restoring the ability of the body to properly utilize carbohydrates, fats, and proteins.
    [Show full text]
  • Antidiabetics – Amylin Analogs Medical Policy No
    Antidiabetics – Amylin Analogs Medical policy no. 27.15.00-1 Effective Date: July 1, 2018 Background: Pramlintide is an amylin analog designed for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy. Amylin is a 37- amino acid peptide that is stored in pancreatic beta cells, is co-secreted with insulin, and has a similar plasma kinetic profile. It affects glucose control through several mechanisms, including slowed gastric emptying, regulation of postprandial glucagon, and reduction of food intake. Glucose influx is better regulated, allowing exogenous insulin therapy to more easily match physiologic needs. Pramlintide is dosed before major meals and titrated as tolerated. Pramlintide has an anorexic effect and carries a black box warning for risk of severe hypoglycemia. Medical necessity Drug Medical Necessity Pramlintide (SYMLIN®, Pramlintide may be considered medically necessary when: SYMLINPEN®) Used for the treatment of type 1 or type 2 diabetes with mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy Clinical policy: Drug Clinical Criteria (Initial Approval) Pramlintide (SYMLIN®, Symlin may be covered when ALL of the following are met: SYMLINPEN®) 1. Diagnosis of Type 1 or Type 2 diabetes 2. Failed to achieve desired glycemic control despite optimal insulin therapy 3. Currently receiving optimal mealtime insulin or continuous insulin infusion (insulin pump) 4. NONE of the following: a. Diagnosis of gastroparesis or requiring medication to stimulate gastrointestinal motility (i.e. metoclopramide or erythromycin) b. Hypoglycemia unawareness (e.g., inability to detect and act upon the signs or symptoms of hypoglycemia) c.
    [Show full text]
  • Annual Report 2016
    Annual Report 2016 Entering a new era Zealand Pharma A/S Company reg. no. 20045078 We are a Danish biotech company discovering and developing novel peptide- based medicines. We are passionate about improving patients’ lives and committed to delivering value for all our stakeholders. We intend to be a world leader in medicines focusing on specialty gastrointestinal and metabolic diseases Zealand Pharma A/S 2 Annual Report 2016 Management review Contents Management Financial review statements About Strategy and partnerships Own clinical pipeline Corporate matters Financial statements In brief 4 Strategy and roadmap 12 Product pipeline 19 Corporate governance 28 Income statement 43 Letter from the CEO 6 Value creation 13 Disease focus 20 Risk management and Statement of internal control 30 comprehensive income 43 Financial highlights 8 Adlyxin®/Lyxumia® 14 Glepaglutide for short bowel syndrome 21 Corporate social Statement of Consolidated key figures 9 Soliqua™ 100/33/Suliqua™ 15 responsibility (CSR) 32 financial position 44 Dasiglucagon for acute, 2016 key events 10 Collaborations with severe hypoglycemia 23 Human resources 33 Statement of cash flows 45 Boehringer Ingelheim and Helsinn 16 Dasiglucagon for Financial review 34 Statement of type 1 diabetes care 25 changes in equity 46 Building the future pipeline 17 Shareholder information 36 Notes 47 Board of Directors 38 Statement of the Senior Management 40 Board of Directors and Executive Management 79 Independent auditor's report 80 Front page: Louise from Molecular Pharmacology, working in one of Zealand's laboratories. Zealand Pharma A/S Annual Report 2016 3 Management review In brief Branded products in diabetes care commercialized by Sanofi Our approach under an exclusive worldwide license We build for success by Lixisenatide is marketed as Adlyxin® in the U.S.
    [Show full text]
  • Zealand Factsheet Based in Denmark – Home to a World-Leading Healthcare Industry
    September 2017 Zealand Pharma A/S Zealand factsheet Based in Denmark – home to a world-leading healthcare industry. – the country with the largest commercial drug development pipeline in Europe, according to investindk.com. Founded in 1998 to design and develop peptide-based medicines. We are a Danish biotech company discovering and developing novel peptide-based medicines. Listed on Nasdaq Dual-listing on Nasdaq in We are passionate about improving patients’ lives and Copenhagen and New York: ZEAL committed to delivering value for all our stakeholders. People We intend to be a world leader in medicines focusing on 130 employees, 80% hereof in R&D specialty gastrointestinal and metabolic diseases. Management Britt Meelby Jensen President and CEO Mats Blom EVP and CFO Zealand Pharma A/S Adam Steensberg EVP and CMO Company reg. no. 20045078 Andrew Parker EVP and CSO In brief Branded products in diabetes care commercialized by Sanofi Disease focus under an exclusive worldwide license Zealand discovers and develops novel peptide-based medicines focusing on specialty gastrointestinal and metabolic diseases Lixisenatide is marketed as Adlyxin® in the U.S. and Soliqua® 100/33 is a combination of lixisenatide and Lantus® is approved as Lyxumia® in more than 60 countries and is marketed by Sanofi in the U.S. The product was worldwide and marketed in over 40 of these by Sanofi. launched as Suliqua® in the first EU country in May 2017. Commercial launches include most EU countries, Japan, Suliqua® will be delivered in two pre-filled SoloSTAR® pens, Gastrointestinal (GI) Brazil, Mexico and India. providing different dosing options.
    [Show full text]